In vitro antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus

Korean Journal of Internal Medicine

Volumn 32, Issue 4, 2017, Pages 731-737

  Lee, Myung Jin ^a,d   Kim, Kye Hyung ^a,b   Yi, Jongyoun ^b   Choi, Su Jin ^c   Choe, Pyoeng Gyun ^a   Park, Wan Beom ^a   Kim, Nam Joong ^a   Oh, Myoung Don ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Gachon University   (South Korea)

Author keywords

Antiviral agents; Bunyaviridae infections; Phlebovirus; Ribavirin

Indexed keywords

RIBAVIRIN; TETRAZOLIUM; ANTIVIRUS AGENT;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BUNYAVIRIDAE; CELL VIABILITY; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DOSE RESPONSE; IN VITRO STUDY; MAXIMAL INHIBITORY CONCENTRATION; NONHUMAN; ONE STEP REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS; VERO CELL LINE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PHLEBOVIRUS; THROMBOCYTOPENIA; TICK BORNE DISEASE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; MICROBIAL SENSITIVITY TESTS; PHLEBOVIRUS; RIBAVIRIN; THROMBOCYTOPENIA; TICK-BORNE DISEASES; VERO CELLS;

EID: 85025151605     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2016.109     Document Type: Article

References (21)

1. Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011;364:1523-1532.
2. Takahashi T, Maeda K, Suzuki T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis 2014;209:816-827.
3. Kim KH, Yi J, Kim G, et al. Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis 2013;19:1892-1894.
4. Liu W, Lu QB, Cui N, et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome. Clin Infect Dis 2013;57:1292-1299.
5. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11 Suppl 4:S750-S761.
6. Rusnak JM. Experience with ribavirin for treatment and postexposure prophylaxis of hemorrhagic fever viruses: Crimean Congo hemorrhagic fever, lassa fever, and han-taviruses. Appl Biosaf 2011;16:67-87.
7. Oh WS, Heo ST, Kim SH, Choi WJ, Han MG, Kim JY. Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome. Int J Infect Dis 2014;18:84-86.
8. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol 1938;27:493-497.
9. Sun Y, Liang M, Qu J, et al. Early diagnosis of novel SFTS bunyavirus infection by quantitative real-time RT-PCR assay. J Clin Virol 2012;53:48-53.
10. Shimojima M, Fukushi S, Tani H, et al. Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro. Jpn J Infect Dis 2014;67:423-427.
11. Shah NR, Sunderland A, Grdzelishvili VZ. Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One 2010;5:e11265.
12. Paragas J, Whitehouse CA, Endy TP, Bray M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res 2004;62:21-25.
13. Ozbey SB, Kader C, Erbay A, Ergonul O. Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2014;14:300-302.
14. Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009;28:929-933.
15. Toltzis P, Huang AS. Effect of ribavirin on macromolec-ular synthesis in vesicular stomatitis virus-infected cells. Antimicrob Agents Chemother 1986;29:1010-1016.
16. Hruska JF, Bernstein JM, Douglas RG Jr, Hall CB. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 1980;17:770-775.
17. Sun Y, Jin C, Zhan F, et al. Host cytokine storm is associ- ated with disease severity of severe fever with thrombocytopenia syndrome. J Infect Dis 2012;206:1085-1094.
18. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986;2:1-14.
19. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010;51:1435-1441.
20. Jin C, Liang M, Ning J, et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model. Proc Natl Acad Sci U S A 2012;109:10053-10058.
21. Liu Y, Wu B, Paessler S, Walker DH, Tesh RB, Yu XJ. The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic fever. J Virol 2014;88:1781-1786.